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Earlier diagnosis: the importance of cancer symptoms
People diagnosed earlier with cancer are not only more 
likely to survive, but importantly also to have better 
experiences of care, lower treatment morbidity, and 
improved quality of life compared with those diagnosed 
late.1 Efforts to improve earlier diagnosis of cancer 
are complex and multifaceted and have been at the 
forefront of international policy and charity (eg, Cancer 
Research UK) initiatives. Two distinct patient behaviours 
can help with earlier cancer diagnosis. These are 
attending cancer screening, which aims to detect cancer 
before it is symptomatic (eg, mammography for breast 
cancer) and presenting promptly to primary care with 
potential cancer symptoms.
The fact that, in England, more than 90% of cancers 
are detected outside the three national screening 
programmes2 (for cervical, breast, and bowel cancers) 
highlights the importance of presenting promptly to 
primary care with potential cancer symptoms. The 
importance of symptomatic presentation is emphasised 
by the growing enthusiasm for campaigns aimed at 
improving public awareness of the early signs of cancer. 
In England, these campaigns come under the umbrella 
of Be Clear on Cancer; however, they are emulated across 
the world, including more recently in low-income and 
middle-income countries such as India, Malaysia, and 
South Africa. One challenge, which so far has remained 
largely unanswered, is whether these campaigns truly 
capture people with early-stage disease and thus 
provide a meaningful contribution to the early diagnosis 
effort. Accumulating evidence shows that they increase 
public awareness, and the likelihood of visiting a doctor, 
being referred for investigations, and being diagnosed 
at an earlier stage of the disease.3,4 However, others have 
argued that the cancers detected are mainly advanced,5 
which would make awareness campaigns less worthy of 
the attention and investment they draw.
In their Article in The Lancet Oncology, Monica Koo 
and colleagues6 present novel epidemiological evidence 
that tackles this issue head on. They used population-
level data from the English National Cancer Diagnosis 
Audit (2014) and looked at 20 common presenting 
symptoms in nearly 8000 patients and their 
association with stage of diagnosis. The data showed 
that the proportion of patients diagnosed with 
advanced disease (ie, stage IV) varied substantially by 
presenting symptom. For example, a neck lump was 
associated with greater odds of advanced disease, 
while symptoms including abnormal mole, breast 
lump, post-menopausal bleeding, and rectal bleeding 
(common symptoms that have already featured in 
public awareness campaigns) were associated with 
lower odds of advanced disease. Looking more broadly, 
for 19 of the 20 symptoms studied, more than a third of 
patients were diagnosed in earlier stages than stage IV. 
Even for symptoms typically associated with advanced 
disease, such as weight loss, more than half of cancers 
were diagnosed in stages other than stage IV. These 
findings provide support for the emphasis on factors 
that are important pre-presentation (eg, knowledge of 
warning signs) because understanding and responding 
to cancer symptoms can help to identify cancer before 
it has spread.
Koo and colleagues’ contribution is an essential 
jigsaw piece in the early diagnosis puzzle, although 
several questions remain. For example, what symptoms 
should be featured? Who should the campaigns be 
targeted at? What barriers (other than poor knowledge 
of warning signs) should they address? How should 
the campaigns be evaluated? It is also crucial to 
ensure campaigns do not serve to escalate persistent 
inequalities in cancer survival,7 so understanding how 
barriers vary by sociodemographic characteristics 
including age, socioeconomic status, and ethnicity 
will be key. Behavioural science has much to add 
here, in terms of identifying important barriers to 
symptomatic presentation such as worry about wasting 
a doctor’s time, fatalism, and fear, as well as designing 
appropriately tailored interventions or campaigns to 
address these barriers.8
Their findings also have important implications for 
health-care professionals because prompt referral 
and investigation of potential cancer symptoms 
post-presentation is another step in ensuring timely 
diagnosis. Research shows that international variation 
exists in the readiness to investigate or refer to 
secondary care for suspected cancer symptoms, and 
countries where health-care professionals demonstrate 
greater readiness observe the highest cancer survival 
rates.9 Finally—a message for policy makers—advocating 
more people going to the doctor, more referrals, 
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https://www.nhs.uk/be-clear-on-
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and more investigations means it is imperative that 
health-care systems have a well equipped and well 
funded workforce to deal with this core and essential 
activity.
Although answers to many of these challenges will 
require an ongoing multidisciplinary and international 
effort, early diagnosis is likely to remain the holy grail 
of cancer care. With this in mind, it is reassuring and 
bolstering to see that global approaches to cancer 
control are on the right track.
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